X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
index medicus (11) 11
oncology (11) 11
female (9) 9
breast cancer (8) 8
adult (5) 5
breast neoplasms - drug therapy (5) 5
antineoplastic agents - therapeutic use (4) 4
cancer (4) 4
history (4) 4
italy (4) 4
male (4) 4
middle aged (4) 4
treatment outcome (4) 4
adolescent (3) 3
aged (3) 3
aged, 80 and over (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
breast neoplasms - pathology (3) 3
care and treatment (3) 3
chemotherapy (3) 3
multicenter (3) 3
1506 (2) 2
administration, oral (2) 2
analysis (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bibliography (2) 2
breast neoplasms - metabolism (2) 2
classification (2) 2
clinical trials (2) 2
clinical trials as topic (2) 2
combined modality therapy (2) 2
double-blind (2) 2
doxorubicin - administration & dosage (2) 2
doxorubicin - adverse effects (2) 2
doxorubicin - therapeutic use (2) 2
experience (2) 2
genes (2) 2
health aspects (2) 2
heart failure (2) 2
hematology, oncology and palliative medicine (2) 2
metaanalysis (2) 2
metastasis (2) 2
metastatic breast cancer (2) 2
mutation (2) 2
non-pegylated liposomal doxorubicin (2) 2
open-label (2) 2
osteosarcoma - drug therapy (2) 2
osteosarcoma - surgery (2) 2
paclitaxel (2) 2
palb2 (2) 2
phase-iii trial (2) 2
quinazolines - therapeutic use (2) 2
receptor, erbb-2 - metabolism (2) 2
remission induction (2) 2
research (2) 2
risk factors (2) 2
safety (2) 2
survival (2) 2
therapy (2) 2
trastuzumab (2) 2
tumors (2) 2
1717 (1) 1
[sdv.mhep]life sciences [q-bio]/human health and pathology (1) 1
acmg-amp guidelines (1) 1
activated protein-kinase (1) 1
adherence (1) 1
adjuvant chemotherapy (1) 1
adjuvant treatment (1) 1
adriamycin (1) 1
advanced breast cancer (1) 1
alternative splicing (1) 1
amp (1) 1
androstadienes - administration & dosage (1) 1
androstadienes - adverse effects (1) 1
angiogenesis inhibitors (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angle resolved xps (1) 1
angle-resolved xps (1) 1
anthracycline-induced cardiotoxicity (1) 1
antibiotics, antineoplastic - administration & dosage (1) 1
antibiotics, antineoplastic - adverse effects (1) 1
antibiotics, antineoplastic - therapeutic use (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal, humanized (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - pharmacology (1) 1
asthma (1) 1
atomic force microscopy (1) 1
atomkraftmikroskopie (1) 1
automation (1) 1
azetidines - pharmacology (1) 1
azetidines - therapeutic use (1) 1
benzenesulfonates - adverse effects (1) 1
beschichtungsverfahren (1) 1
bevacizumab (1) 1
binding proteins (1) 1
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Art - Library use only (2) 2
Robarts - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Music - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Future Oncology, ISSN 1479-6694, 03/2019, Volume 15, Issue 9, pp. 967 - 977
Approximately50% of cutaneous melanomas harbor activating mutations of the BRAF-oncogene, making BRAF inhibitors (BRAFi) the standard treatment for this... 
melanoma | cobimetinib | BRAF inhibitors | MEK inhibitors | MULTICENTER | MUTANT MELANOMA | INHIBITOR-ASSOCIATED RETINOPATHY | OPEN-LABEL | BRAF | T-CELL | METASTATIC MELANOMA | ONCOLOGY | DOUBLE-BLIND | RESISTANCE | VEMURAFENIB | Index Medicus
Journal Article
by Galimberti, Viviana and Cole, Bernard F and Viale, Giuseppe and Veronesi, Paolo and Veronesi, Umberto and Veronesi, Andreas and Vicini, Elisa and Intra, Mattia and Mazzarol, Giovanni and Massarut, Samuele and Zgajnar, Janez and Taffurelli, Mario and Littlejohn, David and Knauer, Michael and Tondini, Carlo and Di Leo, Angelo and Colleoni, Marco and Regan, Meredith M and Coates, Alan S and Gelber, Richard D and Goldhirsch, Aron and Boyle, Fran and Jerusalem, Guy and Stahel, Rolf and Aebi, Stefan and Green, Michael and Karlsson, Per and Kössler, Ingrid and Láng, Istvan and Hiltbrunner, Anita and Bernhard, Jürg and Fournarakou, Stamatina and Kammler, Roswitha and Maibach, Rudolf and Rabaglio, Manuela and Ribi, Karin and Roschitzki, Heidi and Roux, Susanne and Ruepp, Barbara and Mahoney, Caitlin and Price, Karen and Blacher, Lynette and Scolese, Tara and Scott, Karolyn and Lippert, Sandra and Zielinski, Theresa and Mastropasqua, Mauro and Andrighetto, Stefania and Dell'Orto, Patrizia and Renne, Giuseppe and Pruneri, Giancarlo and Dellapasqua, Silvia and Iorfida, Monica and Cancello, Giuseppe and Montagna, Emilia and Cardillo, Anna and Peruzzotti, Giulia and Ghisini, Raffaella and Luini, Alberto and Gentilini, Oreste and Zurrida, Stefano and Curigliano, Giuseppe and Nole, Franco and Orecchia, Roberto and Leonardi, Marisa Cristina and Baratella, Paola and Chifu, Camelia and Sargenti, Manuela and Crivellari, Diana and Morassut, Sandro and Mileto, Mario and Piccoli, Erica and Magri, Marisa Donatella and Buonadonna, Angelo and Candiani, Ezio and Carbone, Antonino and Perin, Tiziana and Volpe, Rachele and Roncadin, Mario and Arcicasa, Mauro and Coran, Francesco and Lagrassa, Manuela and Recalcati, Angelo and Limonta, Maria Emanuela and Tricomi, Paolo and Fenaroli, Privato and Candiago, Elisabetta and Cattaneo, Laura and Gianatti, Alberto and Santini, Donatella and Maweja, Sylvie and Delvenne, Philippe and Rorive, Andrée and Collignon, Joëlle and Garbay, Jean-Remi and Mathieu, Marie-Christine and Galatius, Hanne and Hoffmann, Jack and Schousen, Peer and Lanng, Charlotte and ... and Int Breast Canc Study Grp Trial 23 and International Breast Cancer Study Group Trial 23-01
The Lancet Oncology, ISSN 1470-2045, 10/2018, Volume 19, Issue 10, pp. 1385 - 1393
We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial comparing disease-free survival in patients with breast cancer with one or more... 
SURGERY | WOMEN | MULTICENTER | METASTASIS | ONCOLOGY | LYMPH-NODES | BIOPSY | RECURRENCE | EORTC 10981-22023 AMAROS | Care and treatment | Cancer patients | Breast cancer | Analysis | Surgery
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2012, Volume 134, Issue 1, pp. 283 - 289
Journal Article
Journal Article
Studies in Health Technology and Informatics, ISSN 0926-9630, 2018, Volume 247, pp. 715 - 719
Medical reports often contain a lot of relevant information in the form of free text. To reuse these unstructured texts for biomedical research, it is... 
Text mining | Information extraction | Language | Humans | Information Storage and Retrieval | Natural Language Processing | Biomedical Research | Data Mining | Italy
Conference Proceeding
Annals of Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 766 - 773
Abstract Background Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on... 
paclitaxel | first line | pertuzumab | dual HER2 blockade | HER2-positive | metastatic breast cancer | WEEKLY PACLITAXEL | ONCOLOGY | NAB-PACLITAXEL | PROGRESSION-FREE SURVIVAL | DOCETAXEL
Journal Article
Breast, The, ISSN 0960-9776, 2010, Volume 20, Issue 2, pp. 176 - 183
Abstract Treatment of breast cancer (BC) has changed over the last decade with the advent of targeted therapies. Whereas traditional chemotherapy was directed... 
Hematology, Oncology and Palliative Medicine | Breast cancer | Cardiotoxicity | Targeted therapy | Molecular medicine | TRASTUZUMAB-RELATED CARDIOTOXICITY | CHRONIC HEART-FAILURE | ACTIVATED PROTEIN-KINASE | METASTATIC COLORECTAL-CANCER | OBSTETRICS & GYNECOLOGY | PHASE-III TRIAL | ENDOTHELIAL PROGENITOR CELLS | ONCOLOGY | ANTHRACYCLINE-INDUCED CARDIOTOXICITY | HIGH-DOSE CHEMOTHERAPY | GROWTH-FACTOR | LEFT-VENTRICULAR FUNCTION | Niacinamide - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Antibodies, Monoclonal - adverse effects | Cardiotoxins - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Cardiovascular Diseases - genetics | Benzenesulfonates - adverse effects | Bevacizumab | Heart Failure - prevention & control | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pyrroles - adverse effects | Female | Heart Failure - diagnosis | Angiogenesis Inhibitors - adverse effects | Cardiovascular Diseases - diagnosis | Biomarkers - metabolism | Molecular Targeted Therapy - adverse effects | Risk Assessment | Heart Failure - genetics | Breast Neoplasms - drug therapy | Indoles - adverse effects | Quinazolines - adverse effects | Cardiovascular Diseases - chemically induced | Heart Failure - chemically induced | Trastuzumab | Prevention | Heart failure | Chemotherapy | Cardiac patients | Drug therapy, Combination | Angiogenesis inhibitors | Cardiology | Vascular endothelial growth factor | Health aspects | Endothelium | Cancer | Index Medicus
Journal Article
Journal of the National Cancer Institute Monographs, ISSN 1052-6773, 10/2011, Volume 2011, Issue 43, pp. 147 - 151
Journal Article
by Generali, Daniele and Montemurro, Filippo and Bordonaro, Roberto and Mafodda, Antonino and Romito, Sante and Michelotti, Andrea and Piovano, Pierluigi and Ionta, Maria Teresa and Bighin, Claudia and Sartori, Donata and Frassoldati, Antonio and Cazzaniga, Marina Elena and Riccardi, Ferdinando and Testore, Franco and Vici, Patrizia and Barone, Carlo Antonio and Schirone, Alessio and Piacentini, Federico and Nolè, Franco and Molino, Annamaria and Latini, Luciano and Simoncini, Edda Lucia and Roila, Fausto and Cognetti, Francesco and Nuzzo, Francesco and Foglietta, Jennifer and Minisini, Alessandro Marco and Goffredo, Francesca and Portera, Giuseppe and Ascione, Gilda and Mariani, Gabriella and Elena, Piazza and Rita, Ceccherini and Gabriella, Farina and Mauro, Moroni and Alberto, Tondini Carlo and Saverio, Cinieri and Giuseppe, Cairo and Salvatore, Pisconti and Gennaro, Palmiotti and Francesco, Giotta and Anna, Rizzi and Massimiliano, Spada and Graziella, Pinotti and Francesco, Caruso and Rodolfo, Mattioli and Michele, Aieta and Claudio, Graiff and Claudio, Verusio and Carlo, Aschele and Felettino, Sede and Giovanni, Vicario and Antonella, Ferro and Oscar, Alabiso and Lorenzo, Pavesi and Sergio, Fava and Antonio, Pazzola and Maria, Ruggeri Enzo and Paolo, Tralongo and Monica, Giordano and Maria, D'Arco Alfonso and Vincenza, Tinessa and Teresa, Gamucci Maria and Paolo, Marchetti and Enrico, Cortesi and Ilaria, Portarena and Saverio, Danese and Domenico, Amoroso and Eugenio, Cammilluzzi and Armando, Santoro and Sergio, Bretti and Daniele, Farci and Pietro, Ianniello Giovanni and Salvatore, Palazzo and Antonio, Russo and Giovanni, Rosti and Nicola, Marzano and Evaristo, Maiello and Lorenza, Mairone and Roberto, Maisano and Caterina, Battaglia and Donatella, Grasso and Cesare, Gridelli and Ornella, Garrone and Giuseppe, Serravezza and Laura, Merlini and Cristina, Ghiotto and Silvana, Saracchini and Gianfranco, Filippelli and Andrea, De Censi and Corrado, Ficorella and Corrado, Boni and Pia, Di Stefano and Michela, Donadio and Pierosandro, Tagliaferri and Angelo, Di Leo and Sabino, De Placido and Giuseppina, Sarobba and Federico, Castiglione and Agata, Pisano and ...
The Oncologist, ISSN 1083-7159, 06/2017, Volume 22, Issue 6, pp. 648 - 654
Journal Article
European Journal of Cancer and Clinical Oncology, ISSN 0277-5379, 04/1987, Volume 23, Issue 4, pp. 433 - 436
From 1974 to 1978 29 consecutive patients with operable oesteogenic sarcoma entered 2 successive clinical trials of adjuvant chemotherapy with adriamycin (ADM)... 
Osteosarcoma - drug therapy | Doxorubicin - therapeutic use | Osteosarcoma - mortality | Follow-Up Studies | Humans | Child, Preschool | Male | Combined Modality Therapy | Osteosarcoma - surgery | Adolescent | Adult | Female | Child | Osteosarcoma - therapy
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 12/1993, Volume 72, Issue 11, pp. 3227 - 3238
Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb‐sparing surgery and... 
neoadjuvant chemotherapy | limb salvage | malignant bone tumors | osteosarcoma | ADJUVANT CHEMOTHERAPY | INTRAARTERIAL | MALIGNANT BONE TUMORS | LIMB SALVAGE | HISTOLOGIC TUMOR RESPONSE | CANCER | INTRAVENOUS CISPLATIN | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | OSTEOGENIC-SARCOMA | OSTEOSARCOMA | ADRIAMYCIN | EXPERIENCE | RIZZOLI | Extremities - surgery | Osteosarcoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Femur - pathology | Humerus - surgery | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bone Neoplasms - pathology | Tibia - pathology | Cisplatin - administration & dosage | Adult | Female | Femur - surgery | Bone Neoplasms - drug therapy | Postoperative Complications | Doxorubicin - administration & dosage | Neoplasm Recurrence, Local | Extremities - pathology | Survival Rate | Combined Modality Therapy | Bone Neoplasms - surgery | Remission Induction | Preoperative Care | Tibia - surgery | Humerus - pathology | Methotrexate - adverse effects | Osteosarcoma - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Methotrexate - administration & dosage | Infusions, Intravenous | Osteosarcoma - secondary | Doxorubicin - adverse effects | Osteosarcoma - pathology | Injections, Intra-Arterial | Care and treatment | Osteosarcoma | Adjuvant treatment | Dosage and administration | Methotrexate | Doxorubicin | Cisplatin | Cancer | Extremities (Anatomy)
Journal Article